Theranica develops prescription digital therapeutics that utilize remote electrical neuromodulation to trigger conditioned pain modulation, effectively reducing migraine pain without medication. Their wearable device, Nerivio, stimulates peripheral nerves to enhance the brain's natural pain inhibition mechanisms, providing a safe and drug-free alternative for pain management.
Funding
$87M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NRFounders
Product
Problem
Migraine patients often rely on medication for pain relief, which can lead to side effects and may not be effective for everyone. There is a need for non-pharmacological options that can effectively manage migraine pain without the drawbacks of medication.
Solution
Theranica develops prescription digital therapeutics that use remote electrical neuromodulation (REN) to trigger conditioned pain modulation (CPM), a natural pain-inhibition mechanism in the brain. Their flagship product, Nerivio, is a wearable device that stimulates peripheral nerves in the upper arm to activate CPM, effectively reducing migraine pain without medication. This approach offers a safe and drug-free alternative for migraine management by addressing dysfunctional pain processing through a non-painful, well-felt peripheral stimulus. The stimulation results in the release of neurotransmitters in the brain stem, which shut down the pain.
Target Audience
The primary target audience is individuals who experience migraines and are seeking non-pharmacological pain management options.
Features
- Remote electrical neuromodulation (REN) technology to stimulate peripheral nerves.
- Conditioned pain modulation (CPM) mechanism to activate the brain's natural pain-inhibition system.
- Wearable device that is applied to the upper arm.
- Prescription-based digital therapeutic.
- Drug-free migraine relief.